Dossier · RPAY · Dormant
RPAY · Repay Holdings Corporation
Last analysed ·
Current thesis
Two-activist takeout arb resolved against longs: the board rejected Forager's $4.80 bid (5/4, "significantly undervalues") and closed the $372M debt-funded KUBRA deal (6/1), the defensive move Veradace feared. Stock round-tripped to ~$3.47. What's left is a levered, sub-scale bill-pay name with a ~21% activist block and a 6/10 withhold-vote meeting a deflating special situation.
Invalidation trigger
Forager or Veradace withdraws or converts its Schedule 13D to passive 13G, or the 2026-06-10 meeting re-seats the full board with activists standing down (removes sale optionality); alternatively two consecutive closes below the $3.20 pre-event floor confirm a full fundamental round-trip.
Thesis status
Open commitment catalyst duescored if the trigger above fires How this is scored →Current Thesis
The two-activist takeout arbitrage that defined this name in April has resolved against the long side. The board unanimously rejected Forager Capital's $4.80 cash bid on 2026-05-04 ("significantly undervalues the company") and closed the $372M, debt-funded KUBRA acquisition on 2026-06-01 the exact defensive scenario Veradace warned about when it called for the deal to be abandoned. The stock round-tripped from the ~$4.40–4.70 deal-stub zone to $3.47 (2026-06-05), back inside the pre-event range. What remains is a levered, sub-scale bill-pay processor carrying a ~21% activist block that is running a symbolic withhold-vote campaign into the 2026-06-10 annual meeting. That is residual optionality on a deflating special situation, not an accelerating narrative.
Bull Case
- Activists did not leave after losing the first two rounds: Forager (12.4%, 11,106,648 shares per its Schedule 13D/A) plus Veradace (~8.4%) still hold ~21% combined, and Forager's 2026-06-03 release reiterates that "a transaction involving Repay may be in stockholders' best interests." The pressure block survived the deal close.
- KUBRA adds real scale: the 2026-06-01 close adds $150–154M of revenue and $27.5–30M of Adjusted EBITDA for the final seven months of 2026, lifting reach to over 40% of U.S./Canadian households and ~$130B in combined annual payment volume a larger platform a strategic or PE buyer could still want post-integration.
- Guidance step-up and cheap optics: FY26 revenue guided to $490–500M (from $340–346M) and Adjusted EBITDA to $168.5–176M (from $141–146M) on 2026-06-01. At $3.47 the equity is ~$311M on ~89.7M shares, roughly 4.5–5x EV/EBITDA on the new base inexpensive if activists eventually force a process.
- Sell-side nudged higher post-close: UBS raised its target to $4.25 from $3.75 on 2026-06-03, ~22% above spot (rating held at Neutral).
- Live governance pressure point: the 2026-06-10 annual meeting (contested proxy, DEFC14A filed 2026-05-11) gives the activists a stage; a heavy withhold vote against directors is the kind of public rebuke that has historically pulled entrenched boards back toward engagement.
Bear Case
- The binary already broke the wrong way for longs: the board labeled $4.80 a lowball on 2026-05-04 and then levered the balance sheet with a $500M senior secured term loan (plus a $100M undrawn revolver) to fund KUBRA. Management is building scale to defend independence.
- Round-trip confirmed: from the April activism ramp under the $4.80 anchor to $3.47 on 2026-06-05, the stock now sits below the $3.80 pre-bid resistance and inside the $3.20–3.80 pre-event band. The takeout premium has fully bled out.
- Leverage rewrites the LBO math: ~$500M of new term debt against ~$172M of EBITDA is roughly 3x gross before counting prior obligations. A levered slow-grower is harder and less attractive to take private than the asset-light story Forager pitched in April.
- Organic engine is soft: only 10–12% organic growth guided on 2026-06-01; the headline revenue jump is entirely inorganic KUBRA consolidation, while underlying demand has not accelerated.
- Activist leverage is deflating: the board has already won the two highest-stakes rounds (bid rejection 2026-05-04, deal close 2026-06-01). The 2026-06-03 withhold-vote campaign is a symbolic escalation that stops short of a control bid, and Forager is a ~$4.80-anchored micro-cap activist, not an Elliott-scale operator.
- Sector multiples stay compressed: sub-scale payment processors trade 6–9x EBITDA across the cycle; cheap-and-rolled-over is the value-trap signature.
Setup & Price Structure
- Pre-event range (Feb–early Apr 2026): roughly $3.20–3.80.
- April activism ramp peaked under the $4.80 Forager anchor in the ~$4.40–4.70 deal-stub zone.
- Post-rejection (2026-05-04) and post-KUBRA-close (2026-06-01) the stock bled lower, printing $3.47 on 2026-06-05 with ~6–7% down days reappearing a full retrace.
- Key levels now:
- $4.80 = dead anchor (board rejected; no topping bid in seven weeks)
- $4.25 = UBS target / overhead supply
- $3.80 = former pre-bid resistance, now overhead
- $3.20 = pre-event floor; losing it signals repricing on fundamentals and leverage alone
- This is no longer a momentum chart, and it has not formed a clean base either it is a deflating event stub. RSI and 20-EMA are the wrong lens here; the tape is driven by the June 10 meeting and activist headlines.
Catalyst Calendar (next 30 days)
- 2026-06-10: Annual Meeting / contested proxy (DEFC14A filed 2026-05-11). Forager + Veradace withhold-vote campaign announced 2026-06-03. Watch director vote margins and any post-meeting board statement on engagement.
- ~Mid-to-late June 2026 (est.): probable follow-on Schedule 13D/A from either activist after the meeting escalate, settle, or stand down. This is the real read on whether sale optionality survives.
- ~Early-to-mid August 2026 (est.): Q2 print, the first quarter consolidating KUBRA; tests whether the $490–500M FY26 guide and integration hold. Outside the 30-day window no near-term fundamental binary except the June 10 meeting.
What Would Change Our Mind
- Constructive re-rate: a fresh strategic or PE bid above the dead $4.80 anchor, or a board reversal opening a formal strategic review, would revive the takeout leg and justify fresh exposure.
- Activist win at the meeting: a 2026-06-10 result delivering a large withhold majority plus a concrete board concession (new directors, a strategic committee) would re-arm the activist thesis.
- Optionality death: Forager or Veradace withdrawing or converting its Schedule 13D back to passive 13G status, or publicly dropping the transaction demand after June 10, removes the only catalyst and leaves a levered, slow-growing processor.
- Confirmed downside break: two consecutive closes below the $3.20 pre-event floor signals the market has written off the takeout entirely and is repricing on fundamentals and leverage.
Correlation Notes
- Trades on activism and event idiosyncratics rather than beta low day-to-day correlation to SPX/QQQ; headline gaps dominate the tape.
- Read-through cohort: sub-scale payment processors (Paysafe/PSFE, Shift4/FOUR, Flywire/FLYW, legacy EVO). Sector multiple compression caps any re-rate; a take-private among the group would lift RPAY's takeout optionality.
- KUBRA ties RPAY to the bill-pay and customer-communications vertical (utilities, insurance, government payments), which is more rate-insensitive than card-volume-driven peers a modest defensive tilt.
- Concentration risk: ~21% held by Forager + Veradace creates forced-seller overhang if either fund faces redemptions, a non-fundamental source of pressure independent of the thesis.
Notes
- Event-driven trade standard momentum trim rules (RSI>75
- 20-EMA weekly close) DO NOT apply.
- Two independent activists (Forager + Veradace) watch for third 13D as cascade signal.
- Forager bid is non-binding and financing unconfirmed treat $4.80 as soft ceiling
- not hard floor.
- Poison pill (2026-04-14) is negotiating tool
- not necessarily rejection boards use pills to force process.
- Q1 earnings NOT in 30-day window (historically August) no fundamental binary this cycle
- purely event-driven.
- Sizing cap: 2.5% gross max even at best R/R; arb trades dilute conviction book if oversized.
- Event-driven special sit RESOLVED against the long: board rejected Forager $4.80 on 2026-05-04 and closed the $372M debt-funded KUBRA deal 2026-06-01. Standard momentum trim rules (RSI, 20-EMA) do not apply tape is news/meeting-driven.
- Activist block ~21% intact post-close: Forager 12.4% / 11,106,648 sh (13D/A), Veradace ~8.4%. Withhold-vote campaign into 2026-06-10 annual meeting (DEFC14A filed 2026-05-11). Follow-on 13D/A after the meeting is the key tell on whether sale optionality survives.
- KUBRA funded with a $500M senior secured term loan (+$100M undrawn revolver) RPAY is now ~3x levered, changing the LBO math versus the April asset-light pitch.
- Stock round-tripped to $3.47 (2026-06-05), below $3.80 pre-bid resistance and inside the $3.20-3.80 pre-event range. Loss of $3.20 = fundamental/leverage-only repricing.
- Only 10-12% organic growth guided; FY26 revenue jump to $490-500M is inorganic KUBRA consolidation. UBS Neutral, PT $4.25 (2026-06-03).
- Q2 print ~early-to-mid August 2026 (est.) is the first KUBRA-consolidated quarter outside 30-day window; no near-term fundamental binary except the 6/10 meeting.
- Sizing: deflating special sit with broken structure probe-only if at all; cheap-and-levered carries value-trap risk. Prior 2.5% gross cap guidance still reasonable as a ceiling.
Related · shared themes
MRX
Marex Group plc
Roll-up compounder confirmed by a record Q1 (reported 2026-05-06: revenue +48% to $692M, adj PBT +59%), with the 2026-06-01 Levmet bolt-on extending a 5-deal-in-12-months cadence. But price has run +39.9% in 90 days to ~$55.89, now at the $57.43 consensus PT and just under the $58.62 high the re-rating leg is largely spent. Accumulate pullbacks toward the rising 20-EMA rather than chase the 52-week high.
FWRD
Forward Air Corporation
Strategic review ended with NO buyer (confirmed 2026-05-08) Clearlake/Apollo walked and a ~$250M customer (~10% of revenue) is leaving starting 2027. The deal-premium thesis that was the only reason to watch this is dead; PTs slashed to $17-18, stock cratered ~45% to ~$10. Deleveraging-grind, not a momentum setup. Narrative velocity decisively negative.
IHRT
iHeartMedia, Inc.
M&A special-sit the only live leg decayed from "on ice" (NYT, 2026-05-29) to "fizzled out" (thedesk.net, 2026-06-01) over the same station-divestiture/antitrust impasse; the $6.56 deal-spec spike has fully round-tripped to ~$4.40. No accelerating narrative a mid-5x-levered radio name with Adj EBITDA -11.4% YoY. pass until talks revive with actual terms.
ILMN
Illumina, Inc.
Recognition-phase genomics re-rate that already ran ~96% in a year; now fading from a new $177 high to ~$163 while activist director Corvex/Meister dumps ~$107M into strength and price sits ~13% above the $143.83 avg PT. MATURING with first distribution showing a chase at the highs. Cleaner entry is a hold of the ~$150s base or the early-Aug Q2 confirmation.